An additional short-term pharmacokinetic study of XARACOLL

Trial Profile

An additional short-term pharmacokinetic study of XARACOLL

Planning
Phase of Trial: Phase III

Latest Information Update: 06 Apr 2017

At a glance

  • Drugs Bupivacaine (Primary)
  • Indications Postoperative pain
  • Focus Pharmacokinetics; Registrational
  • Most Recent Events

    • 06 Apr 2017 New trial record
    • 04 Apr 2017 According to a Gurnet point capital media release, an Innocoll has received a Refusal to File Letter from the FDA for XARACOLL and indicated that XARACOLL should be characterized as a drug-device combination product. To support this information an Innocoll has proposed to conduct this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top